These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3888576)

  • 1. Review of self-administration.
    Balster RL; Lukas SE
    Drug Alcohol Depend; 1985 Feb; 14(3-4):249-61. PubMed ID: 3888576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substitution and primary dependence studies in animals.
    Woods JH; Gmerek DE
    Drug Alcohol Depend; 1985 Feb; 14(3-4):233-47. PubMed ID: 4039649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The new mixed agonist-antagonist analgesics, nalbuphine and butorphanol, vs. pentazocine: relapse and substitution in morphine-addict rats.
    Steinfels GF; Young GA; Khazan N
    NIDA Res Monogr; 1981 Feb; 34():138-44. PubMed ID: 6783923
    [No Abstract]   [Full Text] [Related]  

  • 4. Self-administration of nalbuphine, butorphanol and pentazocine by morphine post-addict rats.
    Steinfels GF; Young GA; Khazan N
    Pharmacol Biochem Behav; 1982 Jan; 16(1):167-71. PubMed ID: 7199184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opiate mixed agonist-antagonist interactions with histamine antagonists vs. morphine.
    Hui FW; Sun CL; Hanig JP
    Neurobehav Toxicol Teratol; 1985; 7(5):443-7. PubMed ID: 4080063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discriminative stimulus effects of buprenorphine in the rat.
    Holtzman SG
    Psychopharmacology (Berl); 1997 Apr; 130(3):292-9. PubMed ID: 9151365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of agonistic morphine antagonists (cyclazocine, butorphanol, buprenorphine) on EEG activity and the depth of anesthesia in rats].
    Ogawa T; Sano Y; Hirabayshi Y; Yoshikawa H; Wauquier A; Cuesta P; Clinken B; William M; Van den Broeck
    Masui; 1987 Apr; 36(4):490-7. PubMed ID: 3613060
    [No Abstract]   [Full Text] [Related]  

  • 8. Nalbuphine.
    Schmidt WK; Tam SW; Shotzberger GS; Smith DH; Clark R; Vernier VG
    Drug Alcohol Depend; 1985 Feb; 14(3-4):339-62. PubMed ID: 2986929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of mu-opioid agonists on cocaine- and food-maintained responding and cocaine discrimination in rhesus monkeys: role of mu-agonist efficacy.
    Negus SS; Mello NK
    J Pharmacol Exp Ther; 2002 Mar; 300(3):1111-21. PubMed ID: 11861822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of buprenorphine, butorphanol and nalbuphine on the initiation of intravenous cocaine self-administration in drug naive mice.
    Kuzmin AV; Gerrits MA; Zvartau EE; van Ree JM
    Eur Neuropsychopharmacol; 2000 Dec; 10(6):447-54. PubMed ID: 11115734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nalbuphine, pentazocine, and butorphanol interactions with tripelennamine in mice.
    Schmidt WK; Marynowski ME; Smith C
    NIDA Res Monogr; 1986; 67():145-6. PubMed ID: 3092060
    [No Abstract]   [Full Text] [Related]  

  • 12. Assessment of opioid partial agonist activity with a three-choice hydromorphone dose-discrimination procedure.
    Jones HE; Bigelow GE; Preston KL
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1350-61. PubMed ID: 10336526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid agonist-antagonist drugs in acute and chronic pain states.
    Hoskin PJ; Hanks GW
    Drugs; 1991 Mar; 41(3):326-44. PubMed ID: 1711441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reinforcing and discriminative stimulus properties of mixed agonist-antagonist opioids.
    Young AM; Stephens KR; Hein DW; Woods JH
    J Pharmacol Exp Ther; 1984 Apr; 229(1):118-26. PubMed ID: 6142942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of chronic morphine on behavior reinforced by several opioids or by cocaine in rhesus monkeys.
    Winger G; Woods JH
    Drug Alcohol Depend; 2001 May; 62(3):181-9. PubMed ID: 11295322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The enflurane sparing effect of morphine, butorphanol, and nalbuphine.
    Murphy MR; Hug CC
    Anesthesiology; 1982 Dec; 57(6):489-92. PubMed ID: 7149306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug discrimination in human postaddicts: agonist-antagonist opioids.
    Preston KL; Bigelow GE; Bickel WK; Liebson IA
    J Pharmacol Exp Ther; 1989 Jul; 250(1):184-96. PubMed ID: 2473187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Full ยต-Opioid Receptor Agonists is not Impaired by Concomitant Buprenorphine or Mixed Opioid Agonists/Antagonists - Preclinical and Clinical Evidence.
    van Niel JC; Schneider J; Tzschentke TM
    Drug Res (Stuttg); 2016 Nov; 66(11):562-570. PubMed ID: 27504867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioral pharmacology of buprenorphine.
    Mello NK; Mendelson JH
    Drug Alcohol Depend; 1985 Feb; 14(3-4):283-303. PubMed ID: 3888577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agonist/antagonist properties of nalbuphine, butorphanol and (-)-pentazocine in male vs. female rats.
    Craft RM; McNiel DM
    Pharmacol Biochem Behav; 2003 Apr; 75(1):235-45. PubMed ID: 12759132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.